SynthesisObesity surgery2025
Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis.
Synthesis in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe global rise in obesity and liver disease underscores the significance of bariatric and metabolic surgery (BMS) in treating severe obesity and improving liver function. Although liver failure is often considered a contraindication for elective surgeries, the role of bariatric surgery in patients with compensated cirrhosis has been increasingly explored.
methodsWe systematically searched PubMed, Embase, and Cochrane without temporal restrictions, in January 2025 for randomized controlled trials and observational studies. Statistical analyses were performed using R software. Heterogeneity was assessed with I2 statistics.
resultsThis meta-analysis evaluated BMS's efficacy and safety in patients with cirrhosis by analyzing 26 studies with 22,489 participants. Mortality was 3.33% (95% CI [2.06; 5.35]; I2 = 96.7%). Early postoperative complications were 14.0% (95% CI [7.56; 24.49]; I2 = 90.3%). Patients with cirrhosis had a significant weight loss after 1 year of follow-up (MD -43.06 kg; 95% CI [-70.93; -15.19]; P < 0.0001; I2 = 94.0%), BMI (MD -10.79 kg/m2; 95% CI [-14.45,-7.12]; P < 0.01; I2 = 66.2%), excess weight loss in percentage-EWL% 62.81% (95% CI [52.56; 73.96]; I2 = 78%) and total weight loss in percentage TWL% (26.43% 95% CI [23.89; 28.96]; I2 = 69.3%). The length of stay was 3.77 days ( 95% CI [3.13; 4.42]; I2 = 99.1%).
conclusionDespite increased perioperative risks, mortality remained low, and patients with compensated cirrhosis achieved substantial weight and metabolic improvements, supporting BMS's safety and benefits with proper patient selection.
Indexed as
Identifiers
40900243What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.